Business Context and Reporting Period
Company: Meiwu Technology Company Limited (WNW)
Filing Type: Form 20-F (Annual Report)
Period: Fiscal Year Ended December 31, 2024
Jurisdiction: British Virgin Islands (Holding Company); Operations primarily in China.
Business Overview: The Company is a holding company that underwent a significant strategic pivot in 2024. It terminated its Variable Interest Entity (VIE) structure and exited its former SMS and food e-commerce businesses to focus on a new "functional skincare" business line. The Company is classified as an "emerging growth company" and a "foreign private issuer."
Key Financial Metrics
| Metric (USD) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $158,485 | $10,977,429 | (99%) |
| Net Income (Loss) | $5,114,684 | $(16,312,705) | Turnaround to Profit |
| Gross Profit | $67,131 | $2,583,065 | (97%) |
| Gross Margin | 42.4% | 23.5% | +18.9% |
| Cash and Cash Equivalents | $43,396,977 | $16,062,047 | +170% |
| Total Assets | $60,945,135 | $20,584,279 | +196% |
| Total Liabilities | $1,967,772 | $11,568,372 | (83%) |
| Working Capital | $60.3 Million | $12.8 Million | Significant Increase |
Material Changes vs. Prior Period
- Revenue Collapse: Revenue plummeted 99% to $158,485 due to the cessation of the SMS service business (which previously generated ~77% of revenue) and the termination of the VIE structure associated with food e-commerce operations.
- Profitability Turnaround: Despite the revenue drop, the Company reported a Net Income of $5.1 million in 2024, compared to a Net Loss of $16.3 million in 2023. This was primarily driven by a non-operating Gain on Disposal of Subsidiaries of $8.2 million resulting from the sale of former subsidiaries (Magnum and Xinfuxin) for nominal consideration ($10 each), transferring liabilities to the purchaser.
- Asset Restructuring: Total assets increased significantly due to cash inflows from equity contributions ($47.7 million) and the elimination of liabilities associated with disposed subsidiaries. The Company disposed of its former VIE and related subsidiaries, removing significant liabilities from the balance sheet.
- Business Pivot: The Company launched a functional skincare business (Xiamen Chunshang), which accounted for 38% of the minimal 2024 revenue. The remaining revenue came from legacy food product sales.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management intends to retain earnings to finance the expansion of the new functional skincare business. The strategy involves building a supply chain, partnering with research institutions for product development, and establishing a distributor network in China's second and third-tier cities. No specific financial guidance was provided for future periods.
Material Risks and Contingencies
- Internal Control Weaknesses: Management concluded that internal controls over financial reporting were ineffective as of December 31, 2024. A material weakness was identified regarding the lack of in-house accounting personnel with sufficient US GAAP and SEC reporting experience.
- Regulatory Risks (China): Significant risks exist regarding PRC laws, including the Holding Foreign Companies Accountable Act (HFCAA), cybersecurity reviews, and data privacy regulations. While the PCAOB currently has access to inspect the auditor (Enrome LLP), future restrictions could lead to delisting.
- Liquidity Dependence: As a BVI holding company, the Company relies on dividends from PRC subsidiaries. PRC regulations restrict dividend distributions and currency conversion, which could limit the Company's ability to fund operations or pay dividends.
- Business Transition Risk: The Company has a limited operating history in the functional skincare sector. Success depends on third-party manufacturers, new product acceptance, and the ability to compete with established brands.
Investor Verification Checklist
- Verify the Gain on Disposal: Confirm the details of the $8.2 million gain from the disposal of subsidiaries (Magnum and Xinfuxin) for $10 each. Verify that the liabilities assumed by the purchaser are accurately removed from the balance sheet and that the transaction was arm's length.
- Assess Internal Controls: Review the remediation plan for the identified material weakness in internal controls. Determine if the hiring of outside financial personnel is sufficient to ensure future compliance with SEC reporting standards.
- Validate Skincare Revenue: Scrutinize the $60,227 in revenue from the new functional skincare business. Verify the existence of distributors, the validity of trademark acquisitions, and the sustainability of the supply chain.
- Check Related Party Transactions: Review the $1.29 million in loans due to related parties (including Chairman Changbin Xia) and ensure terms are disclosed and interest-free status is noted.
- Monitor Regulatory Filings: Track the Company's compliance with CSRC filing requirements for overseas listings and any updates regarding PCAOB inspection access to Chinese auditors.